Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-PSMA in mCRPC
NCT04225910Phase 1Unknown
- Sponsor
- Xinhua Hospital
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Ac-225-PSMA in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Xinhua Hospital. Primary endpoint: Prostate-Specific Antigen at 1 year. Status: unknown.
02
Drugs
Ac-225-PSMA
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04225910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225910.